Related Experiment Video

Updated: Jun 13, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Signalling pathways in renal-cell carcinoma: from the molecular biology to the future therapy]

J Edeline1, C Vigneau, J-J Patard

  • 1Service d'anatomie et de cytologie pathologique, pôle cellules et tissus, CHU de Pontchaillou 35033 Rennes cedex 09, France.

Bulletin Du Cancer
|April 27, 2010
PubMed

Insights

Targeted therapies have revolutionized renal-cell carcinoma treatment by targeting key molecular pathways like VHL/HIF/VEGF and PI3K/Akt/mTOR. Understanding these pathways aids in developing better prognostic and predictive factors for clear cell renal-cell carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Renal-cell carcinoma (RCC) treatment has been transformed by targeted therapies.
  • Advances are driven by a deeper understanding of tumor molecular mechanisms.
  • Clear cell renal-cell carcinoma (ccRCC) is the most common subtype.

Purpose of the Study:

  • To review molecular pathways critical for targeted therapies in ccRCC.
  • To explain the mechanisms of action for these targeted therapies.
  • To discuss the role of biological factors in optimizing treatment.

Main Methods:

  • Review of scientific literature on targeted therapies for ccRCC.
  • Description of key molecular pathways: VHL/HIF/VEGF and PI3K/Akt/mTOR.
  • Brief overview of EGFR pathways and other histological subtypes.

Main Results:

  • Identification of VHL/HIF/VEGF and PI3K/Akt/mTOR as central pathways in ccRCC targeted therapy.
  • Explanation of how targeted therapies function at a molecular level.
  • Discussion of the potential for novel prognostic and predictive biomarkers.

Conclusions:

  • Targeted therapies represent a paradigm shift in ccRCC management.
  • Molecular pathway knowledge is essential for current and future drug development.
  • Further research into biomarkers can personalize and improve treatment efficacy.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...